Onya Therapeutics

We are a team of like-minded and determined individuals, all holding a shared vision for the betterment of patient outcomes. We believe that our programmable Smart Materials Platform has the potential to dramatically improve the outcomes in tissue regeneration. We set out to change the industry as we know it, and we are doing just that. Wound care management is a significant healthcare burden. One case that highlights the shortcomings of currently available wound care products is the treatment of “tunnel and undermining” wounds. However, these products do not work in deep tissue/ tunneling/undermining cutaneous wounds due to their depth and irregular shape. There is an urgent clinical needs for a product that fills and heals deep tissue/tunneling/undermining wounds. Gel4Med's Smart Materials Platform is an innovative patent protected self-assembling fiber composition that has been molecularly engineered to simultaneously address the top problems in wound care.

We develop, produce, and sell products that are designed to synergistically achieve the goal that is most satisfying for patients and society - A healed wound. We focus on improving treatments for burns and healing hard-to-heal wounds.

Millions of patients have to live with wounds that do not heal normally, taking months or years to heal. Their numbers are continually growing, their wounds are complex to assess and continually changing. This creates an obstacle course for practitioners working in increasingly constrained health care systems and trying to select the right treatment at the right time. Io-Cyte exists to provide innovative treatments for healing the wound that can be applied in the patient’s home or doctor’s office. Research has told us more than ever about the multiple barriers to healing, such as biofilms, local infection and chronic inflammation, however deciding what is the main obstacle facing a particular wound at any one time is far from straightforward. Io-Cyte are developing dressings that combat multiple healing barriers at once to give the best chance of forming a healthy wound base for healing. The company formed in October 2019 when we identified the potential wound-healing benefits from research in a biomaterials laboratory specialising in biocompatible and absorbent fibre materials. Chris Marsden (Managing Director) has over 25 years’ experience in medical devices, with Zimmer, 3M Healthcare, Johnson & Johnson and other companies. At Johnson & Johnson he was project manager for the development and launch of a bioactive dressing before moving to marketing and commercial roles. His commercial roles include product management, head of marketing role and key account management for US wound care customers. He has been closely involved with design and management of a number of clinical trials in wound healing and surgery. Prior to joining Io-Cyte, Chris was sales and marketing director at Xiros. David Farrar (Research Manager) also Head of New Technologies for Xiros Ltd. Prior to joining Io-Cyte/Xiros David worked for Smith & Nephew for 30 years in a variety of R&D roles but latterly heading up the company’s Biomaterials research programme at its global research centre in York.

Omnio AB is a biopharmaceutical company specializing in the development of new drug products based on the pro-inflammatory and immunoregulatory effects of the protein plasminogen. Omnio focuses on developing recombinant plasminogen for chronic wound healing, where initial physician-led studies of patients with chronic wounds have shown great potential. We develop disruptive treatments that improve lives while lowering the overall cost of health care with plasminogen-based therapeutics. Omnio is led by a team of life science entrepreneurs with extensive experience in immunology, partnerships and drug discovery collaborations. Omnio is developing recombinant plasminogen for treatment of chronic wounds. Our ambition is to change today's wound healing treatment and provide an effective alternative to patients where effective bioactive treatment is lacking. Unlike other products available on the market, plasminogen has been shown to be a key regulatory molecule that activates all stages of the wound healing process. We focus on delivering transformative treatment for chronic wounds and where there is little to no pharmacologically active treatment available today.

Our first wound management product now 510(k) cleared by the FDA. Patent-protected wound healing products based on gentle but effective oxidative chemistry.

We provide convenient at-home, patient-applied therapies that improve patient outcomes and address issues of health equity. We are passionate about providing solutions with outcomes that last. Our products have been proven to deliver sustained healing that saves limbs, helps improve patient quality of life and reduces healthcare costs. Developing differentiated and clinically proven solutions that enable better outcomes for patients and providers. Higher pressure delivery of O2 results in greater tissue diffusion, critical to restoring normal wound metabolism, resulting in more effective and durable healing. Higher pressure delivery results in greater tissue diffusion, upregulating wound metabolism, resulting in faster and more durable healing. We believe all people deserve equal access to effective health care. A seamless addition to a patient’s care plan, our unique suite of products can be used adjunctively without disrupting proven clinical practices and treatment regimens.